Patients after laparoscopic cholecystectomy. Cholecystitis, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Patients receive a 5 mg melatonin tablet (manufactured by Daneshpajoohan Arian Daru Company, Iran) one hour before the procedure. Intervention 2: Control group: Pat
Sponsors
Bandare-abbas University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients aged between 18 and 65 years with ASA I - II Patients who will undergo elective laparoscopic cholecystectomy at Shahid Mohammadi Hospital
Exclusion criteria
Exclusion criteria: Patients undergoing emergency cholecystectomy. Patients with systemic inflammatory response syndrome History of any rheumatological or inflammatory disease Pregnant or breastfeeding patients Patients with a history of sensitivity to melatonin Patients with alcohol or drug abuse Patients with any liver disease Patients with heart, kidney and liver failure Use of narcotics up to 12 hours before the intervention Patients with hemodynamic instability Patients who require laparotomy during surgery Patients treated with systemic corticosteroids
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduce postoperative pain with minimal complications. Timepoint: Pain intensity will be measured and recorded at 1, 6, 12, and 24 hours after surgery. Method of measurement: Pain intensity will be measured with a visual analog scale.;Reduce postoperative inflammation with minimal complications. Timepoint: To assess the effect of melatonin on inflammatory factors, blood samples will be collected from eligible patients undergoing laparoscopic cholecystectomy for complete blood count, erythrocyte sedimentation rate, C-reactive protein, liver function tests, and amylase before and 24 hours after surgery. Method of measurement: to assess the effect of melatonin on inflammatory factors, blood samples will be collected from eligible patients undergoing laparoscopic cholecystectomy for complete blood count, erythrocyte sedimentation rate, C-reactive protein, liver function tests, and amylase. | — |
Secondary
| Measure | Time frame |
|---|---|
| Erythrocyte sedimentation rate. Timepoint: Before surgery and 24 hours after surgery. Method of measurement: Measuring the erythrocyte sedimentation rate in a patient's blood sample.;C reactive protein. Timepoint: Before surgery and 24 hours after surgery. Method of measurement: Measuring its level in a patient's blood sample.;Complete blood count. Timepoint: Before surgery and 24 hours after surgery. Method of measurement: Measuring its level in a patient's blood sample.;Liver function test. Timepoint: Before surgery and 24 hours after surgery. Method of measurement: Measuring its level in a patient's blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahdie Rahrovani
Bandare-abbas University of Medical Sciences
Outcome results
None listed